In vitro evaluation of penta-O-galloyl-β-d-glucose (PGG) on miRNA expression and apoptosis in BCR-ABL⁺ ALL

详细信息    查看全文

• 作者：N.S. Sanddhya^a ; ^{sanddhya_23@yahoo.com} ; R. Stalin^a ; P. Sachdanandam^a ; R. Malathi^b ; P. Shanthi^a ; ^{shanthipalanivelu@gmail.com}
• 关键词：HDACi ; histone deacetylase inhibitors ; ATCC ; the American Type Culture Condition ; PGG ; penta-O-galloyl-β-d-glucose ; ALL ; Acute Lymphoblastic Leukemia
• 刊名：Gene Reports
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：6
• 期：Complete
• 页码：26-31
• 全文大小：497 K
• 卷排序：6

文摘

Acute lymphoblastic leukemia (ALL) is a malignant proliferation of lymphoid cells and BCR-ABL translocation have been reported to have worse prognosis than patients with other sub-types of ALL.One of the underlying mechanisms leading to poor treatment outcome is the aberrant expression of miRNAs that can modulate the epigenetic and genetic pathways leading to survival of cancer cells. Hence, epigenetic regulators are agents that may play a major role in combating this disease which is associated with poor survival rate. The current study aims at investigating the epigenetic modulator penta-O-galloyl-β-d-glucose (PGG) on BCR-ABL+ cell line SUP B1 and BCR-ABL− cell line Jurkat 6.MethodsThe cell viability of the SUP B1 and jurkat 6 cells on treatment with PGG was assessed using Trypan blue staining and FITC-Annexin-V and PI assay was used to determine the apoptotic effect of leukemic cells on treatment. The fold change of the miRNA and mRNA expressions in BCR-ABL cell line were studied using qRT-PCR analysis. By western blotting the protein levels of p53, survivin, caspase 3 and AKT were determinedResultsIn the current study, we demonstrated that PGG had an inhibitory effect on the growth of SUP B1 and Jurkat cells. However, combination therapy of PGG with histone deacetylase inhibitor (HDACi), Vornistat can restore miRNA 203 more effectively than either, as a single agent. Similar results were observed in expression of p53 and other apoptotic regulatory proteins.ConclusionHence, the present study shows that combinational therapy with PGG and Vorinostat has emerged as a promising treatment which has the potential to serve as a novel targeted therapeutic strategy by regulating epigenetic mechanisms in the treatment of BCR-ABL+ ALL